Economy · GS3.1, GS2.6, GS2.3 · 2026-10-18 · 3 min read · 2026-10-18-pm
Centre Caps Trade Margins on Non-Scheduled Cancer Drugs at 30% of MRP
The Union government has capped trade margins on all non-scheduled anti-cancer drugs at 30% of their maximum retail price to reduce patients' out-of-pocket expenses. This move follows evidence of excessive trade mark-ups and aims to make cancer treatment more affordable, a key issue for UPSC aspirants studying health policy and judiciary roles in welfare.
The government capped trade margins on non-scheduled cancer drugs at 30% of MRP to cut high mark-ups and reduce treatment costs.
Why is this in the news?
On October 17, 2026, the Centre announced capping trade margins on non-scheduled cancer drugs to 30% of MRP to reduce high mark-ups and patient costs.
What is the new government measure on cancer drug pricing?
- Trade margin cap. The government capped trade margins on all non-scheduled anti-cancer drugs at 30% of the maximum retail price (MRP) to reduce excessive mark-ups.
- Coverage of drugs. This cap applies to branded and generic drugs, domestically manufactured and imported medicines, and both patented and non-patented products.
- Role of expert committee. An expert committee under the Directorate General of Health Services will finalize the list of medicines covered under this measure.
Why was this intervention necessary?
- High existing mark-ups. The National Pharmaceutical Pricing Authority found average trade mark-ups on non-scheduled anti-cancer drugs around 170%, reaching up to 700% in some cases.
- Financial burden on patients. About 75% of cancer treatment expenditure is borne out of pocket by patients, making affordability a serious concern.
- Market size. The anti-cancer medicines market includes around 225 drugs and 500 formulations, with an annual turnover of approximately ₹12,500 crore.
What impact is expected from the margin cap?
- Price reduction. The intervention is expected to reduce prices by up to 70% of MRP, significantly lowering costs for patients.
- Annual savings. The government estimates cumulative annual savings of around ₹2,500 crore for patients due to this measure.
- Production maintenance. Manufacturers will be required to maintain existing production levels to ensure drug availability despite margin caps.
- Focus on trade margins. The measure regulates trade margins across the distribution chain rather than manufacturers’ selling prices or revenues.
Key numbers
| Figure | What it measures | Source |
|---|---|---|
| 30% | Trade margin cap on non-scheduled cancer drugs as a percentage of MRP | |
| 170% | Average existing trade mark-up on non-scheduled anti-cancer drugs before intervention | |
| 700% | Maximum observed trade mark-up on some non-scheduled anti-cancer drugs | |
| ₹2,500 crore | Estimated annual savings for patients from the margin cap | |
| ₹12,500 crore | Annual turnover of the anti-cancer medicines market | |
| 75% | Proportion of cancer treatment expenditure borne out of pocket by patients |
Back to basics: Drug Pricing and Trade Margins
Trade margin refers to the difference between the maximum retail price of a drug and the price at which it is sold by manufacturers or distributors. Regulating trade margins helps control the final price paid by consumers without directly fixing manufacturers' prices. This is important in healthcare to ensure essential medicines remain affordable while maintaining supply.
Practice: MCQ, Mains and revision
Prelims MCQ
Consider the following statements about the recent government intervention on cancer drug pricing: 1. The government capped trade margins on all non-scheduled anti-cancer drugs at 30% of the maximum retail price. 2. The measure regulates manufacturers’ selling prices directly to reduce costs. Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer and trap
Answer: (a). Statement 2 is incorrect because the intervention targets trade margins across the distribution chain, not manufacturers' selling prices.
Mains question (15 marks)
Examine the role of government intervention and judiciary support in regulating drug prices to improve healthcare affordability in India.
Examine: Discuss how government measures and judicial backing impact drug pricing and patient access to affordable healthcare.
Intro: Government intervention in drug pricing aims to reduce excessive costs and improve healthcare access.
- Explain the mechanism of capping trade margins and its effect on drug prices.
- Discuss the financial burden of cancer treatment on patients and the need for price regulation.
- Analyze the judiciary's supportive role in upholding such measures to protect public health.
Conclusion: Effective government and judicial actions are essential to ensure affordable medicines and reduce out-of-pocket healthcare expenses.
Quick revision
- What is the new trade margin cap on non-scheduled cancer drugs?
- The trade margin is capped at 30% of the maximum retail price.
- How much can trade mark-ups on these drugs reach without regulation?
- Trade mark-ups can reach up to 700% in some cases.
- What annual savings are expected from this margin cap for patients?
- Annual savings of around ₹2,500 crore are expected.
Sources
- [1] The Hindu: Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP · 2026-10-17 · newspaper